admin – Page 2679 – Get News Story

Former Global Ad Executive Chris Macaulay Leads Killara’s Rise in Outdoor Industry

That conviction sparked a bold shift from agency boardrooms to outdoor warehouses, from crafting pitch decks to rebuilding supply chains. In 2023, Macaulay stepped into the outdoor space; not for the aesthetics, but for the opportunity to bring structure, performance, and long-term thinking to a fragmented industry.

Leaving behind a career in global advertising might sound like a gamble; but for Chris Macaulay, it was the start of something far more meaningful.

“I was tired of trading time for money,” says Macaulay, now the CEO of Killara Outdoors, a multi-brand platform company scaling purpose-driven outdoor brands across the U.S. and beyond. “I wanted skin in the game. I wanted to build something real.”

“I didn’t start with a lifelong passion for hunting or fishing,” he admits. “I started with the desire to build something that lasts. But once I got into this space, I saw how broken it was; how many good brands were stuck because they didn’t have the right infrastructure or support.”

Under Macaulay’s leadership, Killara Outdoors has quickly become one of the most respected new players in the industry. With operations across Texas, Colorado, and Hong Kong, Killara now supports a growing portfolio of outdoor brands; including fishing, hunting, tactical, and lifestyle categories; with centralized operations, content strategy, and scalable systems.

The full blog article, From Ads to Altitude: Chris Macaulay’s Leap from Madison Avenue to Mountain Brands, takes a closer look at that career transformation; one that swapped Madison Avenue polish for manufacturing floor grit.

Macaulay’s transition hasn’t just been strategic. It’s been deeply personal. “You stop looking at success in quarterly metrics and start measuring it in people, progress, and legacy,” he says. “That’s the shift that changed everything.”

While many platforms chase trends or volume, Macaulay continues to push Killara in a different direction; one rooted in culture, long-term alignment, and true brand-building.

“This isn’t about exits,” he adds. “It’s about endurance.”

Read the full article at

https://killara.com/blog/from-ads-to-altitude-chris-macaulay-s-leap-from-madison-avenue-to-mountain-brands

Media Contact
Company Name: Killara Outdoors
Email: Send Email
Address:180 State Street, 201
City: Southlake
State: Texas 76092
Country: United States
Website: https://killara.com

BTS Sports Launches to Help Athletes Navigate NIL, Just as Federal Reform Looms

With federal-level NIL legislation gaining steam under proposed reforms by the US Government, one former college athlete is launching a platform designed to help young athletes take control of their name, image, and likeness — before it’s too late.

Giancarlo Coronado, a former walk-on for the San Diego State University baseball team, today announced the official launch of BTS Sports, an athlete-first NIL education and brand development platform. The launch comes amid growing national debate around college athlete compensation and eligibility rules, with the US Government proposing a unified NIL oversight body at the federal level.

For Coronado, the mission is personal.

“I remember being 18 years old and thinking I had all the time in the world,” Coronado says. “Then I got injured, and everything changed overnight. NIL might be new, but the need to be prepared for life after sports? That’s timeless.”

After stepping away from the diamond, Coronado spent several years at a top-tier baseball agency, working alongside elite athletes like Manny Machado, Fernando Tatis Jr., and Albert Pujols on the business side of the game. It was there he saw firsthand how athlete branding, storytelling, and strategic planning shaped careers — both on and off the field.

Now, he’s bringing that playbook to the next generation.

BTS Sports combines NIL rule education, personal branding, and philanthropic training into a modular curriculum tailored to high school and college athletes. From clean profile audits to community engagement planning, the program walks athletes through building a brand rooted in authenticity, compliance, and long-term impact.

The curriculum has already attracted attention from boutique agencies and compliance officers who, due to NCAA regulations, are limited in the advice they can give amateur athletes before they turn pro. BTS bridges that gap — legally and educationally — while offering a clear roadmap for parents and athletes alike.

“Whether you’re a 5-star recruit or fighting for a roster spot, BTS helps you answer three big questions: How do I capitalize with this new opportunity? What actions can I take to positively impact my community? Who are you when the jersey comes off?” says Coronado.

With federal NIL policies potentially on the horizon, experts agree that platforms like BTS Sports may be critical in keeping young athletes eligible, protected, and market-ready.

“Compliance is no longer optional,” Coronado adds. “It’s the difference between playing and watching.”

As NIL continues to evolve, BTS Sports positions itself at the intersection of education, empowerment, and longevity — just in time for the next era of athlete entrepreneurship.

Media Contact
Company Name: BTS Sports
Contact Person: Giancarlo Coronado
Email: Send Email
City: Santee
State: CA
Country: United States
Website: https://bts-sports.com/

Cervical Cancer Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Regeneron Pharma, Akesobio, AstraZeneca, Genexine, Inc., Merck KGaA

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cervical Cancer pipeline constitutes 70+ key companies continuously working towards developing 70+ Cervical Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Cervical Cancer Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cervical Cancer Market.

The Cervical Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cervical Cancer Pipeline Report:

Companies across the globe are diligently working toward developing novel Cervical Cancer treatment therapies with a considerable amount of success over the years.
Cervical Cancer companies working in the treatment market are Rubius Therapeutics, Nurix, PDS Biotechnology Corporation, Vaccibody AS, Roche, EMD Serono, Eli Lilly and Company, AkesoBiopharma, Regeneron Pharmaceuticals, and others, are developing therapies for the Cervical Cancer treatment

Emerging Cervical Cancer therapies such as – RTX 321, DeTIL 0255, PDS 0101, VB10.16, Tiragolumab, Bintrafusp alfa, Gemcitabine, Cadonilimab, Cemiplimab, and others are expected to have a significant impact on the Cervical Cancer market in the coming years.
In July 2025, Tisotumab vedotin (Tivdak), an innovative antibody-drug conjugate (ADC), marks a notable advancement in the treatment of recurrent cervical cancer. This tissue factor-targeting therapy signifies a shift in the current treatment landscape, offering better outcomes in progression-free and overall survival compared to traditional chemotherapy. The study reported an increase in response rates from 5% to 17%. However, experts note that while these results are encouraging, the survival benefits—1.5 months in progression-free survival and 2 months in overall survival—remain modest, underscoring the need for continued progress in cervical cancer treatment.
In March 2025, According to results from the second interim analysis of the Phase 3 KEYNOTE-A18 trial (NCT04221945), presented at the 2025 SGO Annual Meeting on Women’s Cancer, the combination of pembrolizumab (Keytruda) with chemoradiotherapy, followed by pembrolizumab alone, significantly and/or meaningfully improved overall survival (OS) and time to second disease progression or death (PFS2). It also demonstrated a sustained progression-free survival (PFS) advantage compared to chemoradiotherapy alone in patients with newly diagnosed, high-risk, stage IB2 to IIB, node-positive, or stage III to IVA locally advanced cervical cancer.
In May 2025, The FDA awarded fast track designation to ADRX-0706, a Nectin-4-targeting antibody-drug conjugate (ADC), for treating advanced cervical cancer. This designation aims to speed up the development and review of treatments that fulfill urgent medical needs for serious diseases.
In December 2024, The FDA granted fast track designation to CRB-701, a Nectin-4–targeting antibody-drug conjugate (ADC), for the potential treatment of adults with relapsed/refractory metastatic cervical cancer. CRB-701 is a next-generation ADC that incorporates a site-specific, cleavable linker, a uniform drug-to-antibody ratio of 2, and a novel monoclonal antibody targeting Nectin-4. It was designed to overcome the dose-limiting toxicities associated with the linker-payload system used in enfortumab vedotin-efjv (Padcev).
In March 2024, Merck (MSD) has announced that the Phase III KEYNOTE-A18 (ENGOT-cx11/GOG-3047) clinical trial of Keytruda combined with chemoradiotherapy (CRT) in cervical cancer patients has achieved its primary endpoint. This double-blind, randomized trial is being conducted by MSD in collaboration with the European Network for Gynecological Oncology Trial (ENGOT) groups and the GOG Foundation.

Cervical Cancer Overview

Cervical cancer is a type of cancer that develops in the lower part of the uterus, known as the cervix. It usually begins with abnormal cell changes that grow uncontrollably and can spread to nearby tissues if not treated early.

Get a Free Sample PDF Report to know more about Cervical Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight

Emerging Cervical Cancer Drugs Under Different Phases of Clinical Development Include:

RTX 321: Rubius Therapeutics
DeTIL 0255: Nurix
PDS 0101: PDS Biotechnology Corporation
VB10.16: Vaccibody AS
Axalimogene filolisbac: Advaxis
Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.
Tiragolumab: Roche
AK104: Akeso
Bintrafusp alfa: EMD Serono
Durvalumab: AstraZeneca
Gemcitabine: Eli Lilly and Company
HLX10: Shanghai Henlius Biotech
Cadonilimab: AkesoBiopharma
Cemiplimab: Regeneron Pharmaceuticals

Route of Administration

Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Cervical Cancer Pipeline Therapeutics Assessment

Cervical Cancer Assessment by Product Type
Cervical Cancer By Stage and Product Type
Cervical Cancer Assessment by Route of Administration
Cervical Cancer By Stage and Route of Administration
Cervical Cancer Assessment by Molecule Type
Cervical Cancer by Stage and Molecule Type

DelveInsight’s Cervical Cancer Report covers around 70+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Cervical Cancer product details are provided in the report. Download the Cervical Cancer pipeline report to learn more about the emerging Cervical Cancer therapies

Some of the key companies in the Cervical Cancer Therapeutics Market include:

Key companies developing therapies for Cervical Cancer are – Regeneron Pharmaceuticals, Akesobio, AstraZeneca, Genexine, Inc., Merck KGaA, Seagen Inc., Vaccibody AS, Qilu Pharmaceutical Co., Ltd., Genor Biopharma Co., Ltd., Roche, Guangzhou Gloria Biosciences Co., Ltd., Lee’s Pharmaceutical Limited, BeiGene, Henlix Biotech, Biocad, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Cellid Co., Ltd., Innovent Biologics, Zeria Pharmaceutical, Advaxis, Inc., Hookipa Biotech GmbH, GlaxoSmithKline, Iovance Biotherapeutics, Inc., NETRIS Pharma, Rubius Therapeutics, Repertoire Immune Medicines, SOTIO Biotech a.s., VM Oncology, LLC, Andes Biotechnologies, Transgene, Xencor, Inc., Exelixis, Ocellaris Pharma, Inc, Fate Therapeutics, Arcus Biosciences, In., MacroGenics, and others.

Cervical Cancer Pipeline Analysis:

The Cervical Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Cervical Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cervical Cancer Treatment.
Cervical Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cervical Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cervical Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cervical Cancer drugs and therapies

Cervical Cancer Pipeline Market Drivers

Increase in the incidence of oncological disease, large number of ongoing clinical trials are some of the important factors that are fueling the Cervical Cancer Market.

Cervical Cancer Pipeline Market Barriers

However, high cost of therapy, side-effects associated and other factors are creating obstacles in the Cervical Cancer Market growth.

Scope of Cervical Cancer Pipeline Drug Insight

Coverage: Global
Key Cervical Cancer Companies: Rubius Therapeutics, Nurix, PDS Biotechnology Corporation, Vaccibody AS, Roche, EMD Serono, Eli Lilly and Company, AkesoBiopharma, Regeneron Pharmaceuticals, and others
Key Cervical Cancer Therapies: RTX 321, DeTIL 0255, PDS 0101, VB10.16, Tiragolumab, Bintrafusp alfa, Gemcitabine, Cadonilimab, Cemiplimab, and others
Cervical Cancer Therapeutic Assessment: Cervical Cancer current marketed and Cervical Cancer emerging therapies
Cervical Cancer Market Dynamics: Cervical Cancer market drivers and Cervical Cancer market barriers

Request for Sample PDF Report for Cervical Cancer Pipeline Assessment and clinical trials

Table of Contents

1	Cervical Cancer Report Introduction
2	Cervical Cancer Executive Summary
3	Cervical Cancer Overview
4	Cervical Cancer- Analytical Perspective In-depth Commercial Assessment
5	Cervical Cancer Pipeline Therapeutics
6	Cervical Cancer Late Stage Products (Phase II/III)
7	Cervical Cancer Mid Stage Products (Phase II)
8	Cervical Cancer Early Stage Products (Phase I)
9	Cervical Cancer Preclinical Stage Products
10	Cervical Cancer Therapeutics Assessment
11	Cervical Cancer Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Cervical Cancer Key Companies
14	Cervical Cancer Key Products
15	Cervical Cancer Unmet Needs
16	Cervical Cancer Market Drivers and Barriers
17	Cervical Cancer Future Perspectives and Conclusion
18	Cervical Cancer Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cervical Cancer Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Regeneron Pharma, Akesobio, AstraZeneca, Genexine, Inc., Merck KGaA

Schneider Electric Trains On Energy Management

Schneider Electric has surpassed its goal of training some one million people in energy management, a cornerstone of its commitment to inclusive energy transition and youth empowerment.

According to its Q2 2025 extra-financial results released at the weekend, a significant step as it enters the final stretch of its 2021–2025 Schneider Sustainability Impact (SSI) programme, it said the milestone, aligned with World Youth Skills Day 2025, is driven by the Youth Education & Entrepreneurship Programme, active in over 60 countries.

The program, it said, equips underserved communities with technical and entrepreneurial skills to participate in the energy transition.

Commenting on the significance of the empowerment, its Chief Sustainability Officer, Esther Finidori, said: “As an impact company and the World’s Most Sustainable Company, we believe that education is one of the most powerful drivers of long-term transformation. Surpassing 1 million people trained in energy management is a proud moment, and a reminder of what’s possible when purpose meets action. With six months left in our 2021–2025 Schneider Sustainability Impact program, our priority is clear: accelerate with determination and deliver lasting impact.”

Schneider Electric which prides itself as leader in the digital transformation of energy management and automation, said with six months remaining, it will continue to demonstrate its commitment to measurable, inclusive, and transformative progress across its Environmental, Social, and Governance (ESG) goals. The company’s SSI score reached 8.06 out of 10 this quarter, reflecting sustained momentum across key sustainability pillars.

Other significant milestones achieved during the period, according to the result include digital twin technology is used to train displaced communities in solar repair and e-waste recycling in Cox’s Bazar, Bangladesh; the Conserve My Planet program engages students in India, Kenya, Vietnam, and Thailand through hands-on sustainability projects; and mobile training benches bring renewable energy education to incarcerated youth, supporting reintegration and reducing recidivism in Brazil.

Media Contact
Company Name: ABC Private Limited
Contact Person: Media Relations
Email: Send Email
Country: India
Website: https://www.se.com/in/en/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schneider Electric Trains On Energy Management

Liver Cirrhosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland

DelveInsight’s “Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Liver Cirrhosis, historical and forecasted epidemiology as well as the Liver Cirrhosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Liver Cirrhosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Cirrhosis Market Forecast

Some of the key facts of the Liver Cirrhosis Market Report:

The Liver Cirrhosis market size was valued approximately USD 3,100 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In April 2025, Enrollment has been finalized for the Phase 3 NATiV3 clinical trial (NCT04849728), which is evaluating lanifibranor in individuals with metabolic dysfunction-associated steatohepatitis (MASH) and advanced liver fibrosis. According to the developer, Inventiva, if the results are favorable, the top-line data from this global study could support regulatory approval submissions for lanifibranor.
In March 2025, According to two-year data from the Phase 3 MAESTRO-NAFLD-1 clinical trial (NCT04197479), long-term treatment with Rezdiffra (resmetirom) has been shown to reduce liver scarring in most individuals with compensated cirrhosis—irreversible scarring in a still-functioning liver—caused by metabolic dysfunction-associated steatohepatitis (MASH). This finding was recently revealed by Madrigal Pharmaceuticals, the developer of the therapy.
In March 2025, Akero Therapeutics’ experimental therapy efruxifermin has shown the ability to reverse compensated cirrhosis—permanent liver scarring with preserved function—in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. These top-line results come from the Phase 2b SYMMETRY clinical trial (NCT05039450) and were described by the company as both “unprecedented” and statistically significant in a recent press release. The findings align with previous Phase 2b HARMONY trial (NCT04767529) data, which demonstrated that efruxifermin reduced liver fibrosis in patients with MASH who had not yet developed cirrhosis.
In January 2025, Akero Therapeutics has announced preliminary topline results from week 96 of its Phase IIb SYMMETRY study evaluating efruxifermin (EFX) in adults with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, caused by metabolic dysfunction-associated steatohepatitis (MASH). This placebo-controlled, multicenter, double-blind, dose-ranging, randomized trial focused on individuals with the condition.
In December 2024, Galectin Therapeutics revealed findings from its global NAVIGATE clinical trial assessing belapectin in individuals with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
In October 2024, PharmaIN Corporation announced that it will present interim findings from its ongoing Phase I clinical trial of PHIN-214, its leading candidate for preventing and treating decompensated cirrhosis.
In 2023, the market size for liver cirrhosis in the EU4 and the UK was approximately USD 566 million.
In 2023, Germany had the largest market size for liver cirrhosis among EU countries, reaching nearly USD 152 million, while Spain had the smallest, with a market size of approximately USD 77 million.
In 2023, the total number of diagnosed prevalent cases of Liver Cirrhosis in the US was around 2,070 thousand, with expectations for growth throughout the forecast period.
The US alone has the highest number of diagnosed prevalent cases of liver cirrhosis among the 7MM, followed by the EU4, the UK, and Japan, which contribute 24% and 14% of all liver cirrhosis cases, respectively.
The distribution of diagnosed prevalent cases of liver cirrhosis by etiology in Japan revealed that MASH, HCV, HBV, ALD, and PBC accounted for 13%, 45%, 15%, 26%, and 2% of cases, respectively.
In 2023, the EU4 and the UK had approximately 830 thousand diagnosed prevalent cases of liver cirrhosis, with Germany reporting the highest number of cases
Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland Pharma, Lipocine Inc., Intercept Pharma, Sanofi, HK inno.N Corporation, Pfizer, and others
Key Liver Cirrhosis Therapies: Resmetirom, Belapectin, Efruxifermin, LPCN 1148, IDN-6556, NRL972, Resmetirom, GXHPC1, GI262570, Rifaximin, BMS-986263, MNK6106, conivaptan, LPCN 1148, INT-747, Satavaptan, oltipraz, Obeticholic Acid (OCA), IDN-6556, Pregabalin, and others
The Liver Cirrhosis epidemiology based on gender analyzed that males are more affected with Liver Cirrhosis than females
The Liver Cirrhosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Cirrhosis pipeline products will significantly revolutionize the Liver Cirrhosis market dynamics.

Liver Cirrhosis Overview

A late-stage liver condition called liver cirrhosis causes the liver to become irreversibly damaged when good liver tissue is replaced with scar tissue.

Get a Free sample for the Liver Cirrhosis Market Report

https://www.delveinsight.com/report-store/liver-cirrhosis-market

Liver Cirrhosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Liver Cirrhosis Epidemiology Segmentation:

The Liver Cirrhosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Liver Cirrhosis
Prevalent Cases of Liver Cirrhosis by severity
Gender-specific Prevalence of Liver Cirrhosis
Diagnosed Cases of Episodic and Chronic Liver Cirrhosis

Download the report to understand which factors are driving Liver Cirrhosis epidemiology trends @ Liver Cirrhosis Epidemiology Forecast

Liver Cirrhosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Cirrhosis market or expected to get launched during the study period. The analysis covers Liver Cirrhosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Liver Cirrhosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Liver Cirrhosis Therapies and Key Companies

Resmetirom: Madrigal Pharmaceuticals Inc.
Belapectin: Galectin Therapeutics
Efruxifermin: AkeroTherapeutics
LPCN 1148: Lipocine Inc
IDN-6556: Conatus Pharma
NRL972: Norgine
Resmetirom: Madrigal Pharma
GXHPC1: Gwo Xi Stem Cell Applied Tech
GI262570: GlaxoSmithKline
Rifaximin: Bausch Health
BMS-986263: Bristol-Myers Squibb
MNK6106: Mallinckrodt
conivaptan: Cumberland Pharma
LPCN 1148: Lipocine Inc.
INT-747: Intercept Pharma
Satavaptan: Sanofi
oltipraz: HK inno.N Corporation
Obeticholic Acid (OCA): Intercept Pharma
IDN-6556: Conatus Pharmaceuticals Inc.
Pregabalin: Pfizer

Discover more about therapies set to grab major Liver Cirrhosis market share @ Liver Cirrhosis Treatment Market

Scope of the Liver Cirrhosis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland Pharma, Lipocine Inc., Intercept Pharma, Sanofi, HK inno.N Corporation, Pfizer, and others
Key Liver Cirrhosis Therapies: Resmetirom, Belapectin, Efruxifermin, LPCN 1148, IDN-6556, NRL972, Resmetirom, GXHPC1, GI262570, Rifaximin, BMS-986263, MNK6106, conivaptan, LPCN 1148, INT-747, Satavaptan, oltipraz, Obeticholic Acid (OCA), IDN-6556, Pregabalin, and others
Liver Cirrhosis Therapeutic Assessment: Liver Cirrhosis current marketed and Liver Cirrhosis emerging therapies
Liver Cirrhosis Market Dynamics: Liver Cirrhosis market drivers and Liver Cirrhosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Liver Cirrhosis Unmet Needs, KOL’s views, Analyst’s views, Liver Cirrhosis Market Access and Reimbursement

To know more about Liver Cirrhosis companies working in the treatment market, visit @ Liver Cirrhosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Liver Cirrhosis Market Report Introduction

2. Executive Summary for Liver Cirrhosis

3. SWOT analysis of Liver Cirrhosis

4. Liver Cirrhosis Patient Share (%) Overview at a Glance

5. Liver Cirrhosis Market Overview at a Glance

6. Liver Cirrhosis Disease Background and Overview

7. Liver Cirrhosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Liver Cirrhosis

9. Liver Cirrhosis Current Treatment and Medical Practices

10. Liver Cirrhosis Unmet Needs

11. Liver Cirrhosis Emerging Therapies

12. Liver Cirrhosis Market Outlook

13. Country-Wise Liver Cirrhosis Market Analysis (2020–2034)

14. Liver Cirrhosis Market Access and Reimbursement of Therapies

15. Liver Cirrhosis Market Drivers

16. Liver Cirrhosis Market Barriers

17. Liver Cirrhosis Appendix

18. Liver Cirrhosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Liver Cirrhosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland

Boost Brand Visibility with Custom T Shirt, Name Card, and Poster Printing in Singapore

In the saturated marketplace of Singapore, standing out visually is a strategic advantage. Whether for corporate events, product launches, marketing campaigns, or daily business operations, professionally printed materials communicate brand identity, professionalism, and reliability. Services like custom t shirt printing Singapore, name card printing Singapore, and poster printing Singapore play a crucial role in shaping public perception and driving brand engagement.

Custom T Shirt Printing Singapore: Branded Apparel that Makes a Statement

Branded t-shirts serve as powerful walking billboards. With custom t shirt printing Singapore, companies, schools, and event organizers can produce visually appealing apparel that enhances team spirit, reinforces brand identity, or captures the attention of target audiences.

T-shirts printed with high-quality techniques — such as silkscreen, DTG (direct-to-garment), or vinyl heat transfer — offer durability and sharp detail. Whether for staff uniforms, promotional giveaways, or merchandise, the right design paired with quality fabric can boost perceived brand value.

Design flexibility is a major benefit of custom t shirt printing in Singapore. Graphics, logos, slogans, and even full-color illustrations can be printed in a variety of styles to match the tone and purpose of the brand or event. Minimalist prints suit corporate functions, while bold, colorful designs may suit streetwear-inspired marketing campaigns. Bulk printing options also allow businesses to scale up while keeping costs efficient.

Name Card Printing Singapore: First Impressions that Last

In Singapore’s business culture, exchanging name cards remains a vital networking ritual. Professionally printed cards serve as more than contact tools — they signal brand identity, professionalism, and attention to detail. Name card printing Singapore services offer numerous customization options to align with branding goals.

Design elements such as premium cardstock, matte or gloss lamination, spot UV finishes, embossing, and foil stamping can be combined to create name cards that leave a strong impression. A well-designed name card communicates seriousness and preparedness — qualities that matter in high-stakes networking scenarios.

Consistency is key. A name card should reflect the same visual tone as the brand’s other touchpoints, such as website, packaging, and promotional materials. High-resolution logos, readable fonts, and balanced layouts contribute to a clean, professional appearance.

Quick turnaround times and short-run capabilities from local printers also allow startups and small businesses to test designs or print in limited quantities without high upfront costs. For larger corporations, bulk printing with automated fulfillment can streamline distribution across departments.

Poster Printing Singapore: Capture Attention in One Glance

When visibility is the goal, large-format visuals deliver. Poster printing Singapore is an effective solution for brands seeking to attract foot traffic, advertise promotions, or decorate physical spaces with branded content.

High-quality poster printing enables the use of vibrant colors, sharp text, and durable materials suitable for both indoor and outdoor environments. Whether displayed in retail windows, event venues, or office lobbies, posters help communicate key messages at a glance.

Standard sizes like A2, A1, and A0 are commonly used, but custom dimensions can be produced to suit specific display areas. Mounting options like foam boards, canvas, and laminates are available for more premium applications.

For marketing campaigns, posters serve as call-to-action tools, driving customers toward a store, website, or event. In corporate settings, posters can reinforce internal messaging, safety protocols, or company values. Their versatility makes poster printing in Singapore a valuable asset for both commercial and internal branding.

Integrating Print into a Cohesive Brand Strategy

Bringing together custom t shirt printing, name card printing, and poster printing within a unified design system reinforces brand consistency across touchpoints. Colors, fonts, messaging, and tone should align across all printed materials to strengthen brand recognition.

For example:

– A company launching a new service may create staff t-shirts with bold typography, hand out custom-printed name cards at roadshows, and hang large-format posters in shared co-working spaces.

– A retail brand running a holiday campaign may use t-shirts for frontline staff, name cards for networking at trade shows, and window posters to draw attention to in-store promotions.

Print materials remain a crucial part of Singapore’s business communication landscape, even in the digital age. When done right, they serve as tangible proof of a brand’s professionalism and attention to detail.

Investing in custom t shirt printing Singapore, name card printing Singapore, and poster printing Singapore creates multiple touchpoints for brand exposure and customer engagement. With the right combination of design, quality, and strategic placement, printed materials continue to deliver strong returns on visibility, memorability, and trust.

Media Contact
Company Name: PrintVolution
Contact Person: John
Email: Send Email
Country: Singapore
Website: https://printvolution.sg/product/art-posters/poster/

“Serve AI” Launches Free for Toast Customers, Bringing Powerful Restaurant Intelligence to Operators Nationwide

Kansas City, KS – August 5, 2025 – Serve AI, a restaurant intelligence platform designed for busy operators, is now available at no cost for all Toast customers. This move brings powerful insights and automation to restaurants across the country, without adding to their software spend or operational complexity.

Serve AI integrates directly with a restaurant’s existing Toast POS system, analyzing performance trends, monitoring online reviews, and flagging potential issues automatically. With this new offering, Serve AI is giving restaurants access to enterprise-grade tools that were previously out of reach for many independent and multi-unit operators.

“Restaurants are being asked to do more with less,” said Ben York, CEO at Serve AI. “Serve was created to take work off their plates. Now that it’s free for Toast customers, any operator can unlock real-time insights and protect their bottom line without a major investment.”

Key Features of Serve AI Now Available to Toast Users

Performance alerts that notify operators when sales drop, labor costs spike, or store-level metrics fall below expectations
Automated monitoring of reviews across platforms like Google, Yelp and Reddit, including suggested responses to negative feedback
Competitive visibility into local pricing, SEO performance, AI zero click search, and guest sentiment to stay ahead in a crowded market
Marketing toolkit that generates content in customized brand voice to help promote specials, menu features, events, and more across social media and email campaigns
Seamless setup through Toast with no complex onboarding or IT resources required

During a recent interview, Randy Barnett, Chief Technology Officer of The Melting Pot Restaurants, Inc., made these comments, “Serve AI gives us the operational clarity we’ve needed — it’s like flipping on the lights across the entire system. From the moment we started using it, our teams were able to move faster and act with more confidence. It’s transforming how we operate.”

Serve AI offers restaurant teams the ability to make faster, more informed decisions without logging into multiple systems or hiring outside analysts. The free integration with Toast ensures that these tools are accessible to a wide range of operators navigating an increasingly competitive industry.

To learn more or activate Serve AI, visit: https://www.serveitup.ai/

About Serve AI

Serve AI is an intelligent operations platform for restaurants and hospitality businesses. It helps teams surface trends, monitor feedback, and take smarter actions in real time. By integrating with the tools restaurants already use, Serve AI simplifies decision-making and helps operators grow revenue with less effort.

Media Contact
Company Name: ServeItUp.Ai
Contact Person: Chloe Austin, VP Marketing
Email: Send Email
Phone: 785-341-1605
City: Kansas City
State: KS
Country: United States
Website: https://www.serveitup.ai/

Shore Homecare Continues to Offer Comprehensive 24-Hour Home Care in Lakewood, NJ.

A joyful moment between a senior and her caregiver captures the warmth and trust that define true around-the-clock support. This image reflects the mission behind Shore Homecare Continues to Offer Comprehensive 24-Hour Home Care in Lakewood, NJ, ensuring families experience peace of mind while their loved ones receive compassionate care day and night.

Shore Homecare reaffirms its commitment to providing 24-hour home care in Lakewood, NJ, ensuring families have continuous, compassionate support for loved ones. With professionally trained caregivers offering round-the-clock assistance, clients benefit from enhanced safety, companionship, and quality of life. This service promotes peace of mind for families and enables seniors to remain comfortably and securely in their homes.

Lakewood, NJ – Shore Homecare, a trusted provider of in-home senior services, today reaffirms its commitment to the Lakewood community by continuing to offer its comprehensive 24-hour home care services. This ongoing initiative ensures that families have a reliable and professional option for loved ones who require constant assistance and supervision, allowing them to remain safely in the comfort of their own homes.

A primary benefit of this service is the uninterrupted safety and supervision it provides. For seniors and individuals with complex health needs, having a caregiver present at all times significantly reduces emergencies, especially during the vulnerable nighttime hours. This constant presence guarantees immediate assistance with mobility, personal care, and any urgent needs, offering unparalleled peace of mind to family members who cannot be there around the clock.

Furthermore, the service greatly enhances the client’s overall quality of life. The consistent support provided through 24-hour care at home in Lakewood, NJ, helps to alleviate feelings of loneliness and isolation. Caregivers offer not only physical assistance with daily tasks like meal preparation and light housekeeping but also crucial companionship and emotional support. This holistic approach fosters a dignified, engaging, and comfortable living environment for clients.

“Our mission has always been to provide families with the assurance that their loved ones are safe, comfortable, and well-cared for in their own homes,” said Fernando Reinoso, owner of Shore Homecare. “By reaffirming our commitment to providing 24-hour home care in Lakewood, NJ, we want to ensure that no family in our community feels they have to face the challenges of round-the-clock care alone. We are here to be their care partners.”

A dedicated team delivers Shore Homecare’s 24-hour care of compassionate and professionally trained caregivers. To ensure clients receive alert and responsive support, care is typically managed in shifts. Each care plan is fully customized after an in-depth, in-home assessment to meet the specific medical, personal, and social needs of the individual client.

For more information about Shore Homecare Services and their 24-hour home care in Lakewood, NJ, please visit their website at https://shorehomecareservices.com.

About Shore Homecare Services:

Shore Homecare is a premier home care agency serving Lakewood, NJ, and the surrounding communities. The agency is dedicated to providing compassionate, professional, and personalized care services, ranging from companion care to 24-hour assistance, enabling clients to live safely and comfortably in their own homes.

Media Contact
Company Name: Shore Homecare Services
Contact Person: Fernando Reinoso
Email: Send Email
Phone: +1 732 534 5000
Address:19 N County Line Rd Suite #13
City: Jackson Township
State: NJ
Country: United States
Website: https://shorehomecareservices.com

Space City Toyota Approaches One-Year Rebrand Milestone, Reinforcing Its Role as a Premier Toyota Dealership in Houston

The dealership celebrates a year of continued growth under Vaughan Automotive, expanding its presence in the Greater Houston automotive market.

Space City Toyota, a full-service Toyota dealership serving North Houston, is proud to mark a major milestone: nearly one year since its official rebrand under Vaughan Automotive in September 2024. This achievement reflects the store’s steady growth and expanding impact in the local automotive market.

The milestone highlights Space City Toyota’s successful relaunch as a modern Toyota dealership in Houston, focused on access, transparency, and long-term customer service. Since its rebrand, the dealership has grown its customer base and operations while offering an extensive inventory of new Toyota vehicles, certified service, and digital buying tools.

“Our goal is to bring a new energy and experience to customers across North Houston,” said David Vaughan, managing partner of Vaughan Automotive, in a 2024 interview with Auto Dealer Today. “We’re excited about the opportunity to serve this market and look forward to growing alongside the community.”

Space City Toyota attributes its continued growth to its team of experienced professionals, commitment to service, and support from the Vaughan Automotive network. The dealership offers Toyota’s most popular models, including the Tundra, Tacoma, Camry, and Prius, along with on-site maintenance and finance solutions tailored to local drivers.

Looking ahead, Space City Toyota plans to continue investing in technology, customer convenience, and local engagement as it builds on its first full year under its new brand identity.

About Space City Toyota

Space City Toyota is a full-service Toyota dealership located in Humble, Texas. Part of Vaughan Automotive, the dealership offers new and pre-owned Toyota vehicles, certified service, OEM parts, and financing solutions to drivers throughout North Houston and surrounding areas.

Media Contact
Company Name: Space City Toyota
Contact Person: Ben Saxton
Email: Send Email
Country: United States
Website: https://www.spacecitytoyota.com

Swoop’s first fibre-to-the-premises network

Swoop Infrastructure launches its first fibre-to-the-premises network in WA, connecting 1,000 homes in Geraldton with ultra-fast speeds up to 8 Gbps—marking a major step in delivering future-ready broadband to regional Australia.

We’re proud to announce a major milestone for Swoop Infrastructure (Swoop’s wholesale network arm), the successful deployment of our first fibre-to-the-premises (FTTP) wholesale network in Western Australia.

This cutting-edge network connects 1,000 homes in Geraldton’s Seacrest Estate with ultra-fast broadband speeds of up to 8 Gbps.

This is a key step in our strategy to deliver high-speed, future-ready broadband to regional communities. By rolling out our own fibre infrastructure, we’re giving developers and residents more choice and access to premium broadband solutions.

Bringing future-ready broadband to regional Australia

Led by Swoop Infrastructure, the Seacrest Estate deployment shows our ability to deliver high-performance broadband solutions.

With streaming, gaming, remote work, smart home devices, and cloud services all increasing rapidly, the demand for reliable and fast internet is growing. Our network has been built to meet these demands, not just for today, but well into the future.

Alex West, CEO of Swoop, shared the company’s broader vision:

“This is an exciting time for Swoop as we start to focus on fibre infrastructure to ensure that we continue our journey in delivering high-speed broadband to underserved areas in Australia by using our state-of-the-art fibre broadband technology.”

This landmark project represents the next big step in our infrastructure capabilities. giving developers and regional communities greater choice, performance, and access to future ready broadband.

A strategic shift to infrastructure

This deployment is part of a broader focus for Swoop Infrastructure as we expand our fibre offerings alongside our existing fixed wireless capabilities. For both single-dwelling and multi-dwelling units, Swoop can support the infrastructure needs of developers and communities alike.

“We’re proud to deliver a fibre network that not only offers state-of-the-art speed and performance but is also built to scale with the expected consumer data demands into the future,” said our Head of Infrastructure, Anthony Camilleri.

Partnering for stronger communities

We believe regional areas deserve the same digital opportunities as metro centres. That’s why we’re working closely with developers, local councils, and building owners to roll out scalable fibre solutions that truly support connected communities.

“Swoop has a deep legacy in serving regional Australia, and this next-generation infrastructure is just the beginning of what we can deliver in partnership with forward-thinking developers, councils, body corporates, and building owners,” added Camilleri.

What’s next for Swoop?

With the completion of this network in Western Australia, we’re just getting started. We are committed to growing our presence in regional areas by delivering flexible, high-speed broadband solutions where they’re needed most.

With both fibre and fixed wireless services in our toolkit, Swoop can be a complete infrastructure partner. This project is just the beginning of what we can deliver in collaboration with forward thinking developers, councils, and communities, especially in regional and underserved areas.

A big thank you to our incredible team who continue to push boundaries and bring our vision to life. We’re excited for what’s ahead.

About Swoop

Swoop is a national provider of data and voice services to wholesale, business and residential customers with a focus on its own fibre and fixed wireless infrastructure. The Swoop network is designed and scaled to deliver ultra-reliable, high throughput, flexible telecom network services. Swoop is established and has the goal to build its business to become Australia’s best challenger internet and telecommunications provider.

For further media information contact:

David Michaels, Chief Revenue Officer

hello@swoop.com.au

www.swoop.com.au

Media Contact
Company Name: Swoop Holdings Limited
Contact Person: David Michaels, Chief Revenue Officer
Email: Send Email
Phone: 0438 441 594
Address:Level 5, 126-130 Phillip Street
City: Sydney
State: NSW
Country: Australia
Website: https://www.swoop.com.au

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Swoop’s first fibre-to-the-premises network